Replies to post #840 on BioLife Solutions Inc (BLFS)

[conix]

BioLife Solutoins, Inc Is Fundamental To Cell And Gene Therapy

BioLife Solutions, Inc (NASDAQ: BLFS) is uniquely positioned in that it is a supplier of highly specialized equipment for the cell and gene therapy industries. While not a health care company itself it is fundamental to the industry and a company whose stock is on the move. Not only did the company deliver a solid 77% increase in YOY revenue but it announced a game-changing acquisition and got an important upgrade to boot.

The acquisition is Global Cooling, the parent company of Stirling Ultracold, a manufacturer of ultra-low temperature mechanical freezers. The deal is an all-stock transaction that will grow BioLife Solutions revenue by 80% by the end of the year with accretive impact to bottom-line results in 2022. The upgrade comes from Benchmark and is from Neutral to Buy. The price target is $54 or 40% from upside from Monday’s close but don’t rush to buy just yet. The premarket action has this stock up 20% so we suggest waiting for a pullback before making any decisions.